Literature DB >> 32507013

A novel microRNA boosts hyper-β-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPARα and thus restricts chronic hepatitis C.

Suchandrima Ghosh1, Joyeeta Chakraborty2, Avijit Goswami3, Sayantani Bhowmik1, Susree Roy1, Amit Ghosh1, Sakshi Dokania1, Priyanka Kumari1, Simanti Datta1, Abhijit Chowdhury4, Suvendra Nath Bhattacharyya3, Raghunath Chatterjee2, Soma Banerjee1.   

Abstract

Imbalance in lipid metabolism induces steatosis in liver during Chronic hepatitis C (CHC). Contribution of microRNAs in regulating lipid homoeostasis and liver disease progression is well established using small RNA-transcriptome data. Owing to the complexity in the development of liver diseases, the existence and functional importance of yet undiscovered regulatory miRNAs in disease pathogenesis was explored in this study using the unmapped sequences of the transcriptome data of HCV-HCC liver tissues following miRDeep2.pl pipeline. MicroRNA-c12 derived from the first intron of LGR5 of chromosome 12 was identified as one of the miRNA like sequences retrieved in this analysis that showed human specific origin. Northern blot hybridization has proved its existence in the hepatic cell line. Enrichment of premiR-c12 in dicer-deficient cells and miR-c12 in Ago2-RISC complex clearly suggested that it followed canonical miRNA biogenesis pathway and accomplished its regulatory function. Expression of this miRNA was quite low in CHC tissues than normal liver implying HCV-proteins might be regulating its biogenesis. Promoter scanning and ChIP analysis further revealed that under expression of p53 and hyper-methylation of STAT3 binding site upon HCV infection restricted its expression in CHC tissues. Centrosomal protein 350 (CEP350), which sequestered PPARα, was identified as one of the targets of miR-c12 using Miranda and validated by luciferase assay/western blot analysis. Furthermore, reduced triglyceride accumulation and enhanced PPARα mediated transcription of β-oxidation genes upon restoration of miR-c12 in liver cells suggested its role in lipid catabolism. Thus this study is reporting miR-c12 for the first time and showed its' protective role during chronic HCV infection.

Entities:  

Keywords:  HCV; Lipid metabolism; hepatitis C virus; microrna; novel microRNA

Year:  2020        PMID: 32507013      PMCID: PMC7549687          DOI: 10.1080/15476286.2020.1768353

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  57 in total

Review 1.  Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome.

Authors:  Zdenko Herceg; Anupam Paliwal
Journal:  Mutat Res       Date:  2011-04-15       Impact factor: 2.433

2.  Differential expression profiles of sense and antisense transcripts between HCV-associated hepatocellular carcinoma and corresponding non-cancerous liver tissue.

Authors:  Kentaro Nagai; Keisuke Kohno; Mitsuru Chiba; Sugiru Pak; Soichiro Murata; Kiyoshi Fukunaga; Akihiko Kobayashi; Hiroshi Yasue; Nobuhiro Ohkohchi
Journal:  Int J Oncol       Date:  2012-02-21       Impact factor: 5.650

3.  Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.

Authors:  Amit Ghosh; Alip Ghosh; Somenath Datta; Debanjali Dasgupta; Soumyajit Das; Sukanta Ray; Subash Gupta; Simanti Datta; Abhijit Chowdhury; Raghunath Chatterjee; Saroj Kant Mohapatra; Soma Banerjee
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

4.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.

Authors:  L E Adinolfi; M Gambardella; A Andreana; M F Tripodi ; R Utili; G Ruggiero
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.

Authors:  Takayoshi Shirasaki; Masao Honda; Tetsuro Shimakami; Rika Horii; Taro Yamashita; Yoshio Sakai; Akito Sakai; Hikari Okada; Risa Watanabe; Seishi Murakami; MinKyung Yi; Stanley M Lemon; Shuichi Kaneko
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  Interferon modulation of cellular microRNAs as an antiviral mechanism.

Authors:  Irene M Pedersen; Guofeng Cheng; Stefan Wieland; Stefano Volinia; Carlo M Croce; Francis V Chisari; Michael David
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

7.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

Authors:  L Castéra; C Hézode; F Roudot-Thoraval; A Bastie; E-S Zafrani; J-M Pawlotsky; D Dhumeaux
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 8.  Modulation of Lipid Droplet Metabolism-A Potential Target for Therapeutic Intervention in Flaviviridae Infections.

Authors:  Jingshu Zhang; Yun Lan; Sumana Sanyal
Journal:  Front Microbiol       Date:  2017-11-28       Impact factor: 5.640

9.  Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R.

Authors:  Jonathan K Mitchell; Bentley R Midkiff; Benjamin Israelow; Matthew J Evans; Robert E Lanford; Christopher M Walker; Stanley M Lemon; David R McGivern
Journal:  MBio       Date:  2017-04-25       Impact factor: 7.867

10.  HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis.

Authors:  Keng-Hsin Lan; Meei-Ling Sheu; Shinn-Jang Hwang; Sang-Hue Yen; Shiow-Yi Chen; Jaw-Ching Wu; Yuan-Jan Wang; Naoya Kato; Masao Omata; Full-Young Chang; Shou-Dong Lee
Journal:  Oncogene       Date:  2002-07-18       Impact factor: 9.867

View more
  1 in total

Review 1.  Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.